abrdn Life Sciences Investors Shares of Beneficial Interest
Find Ratings Reports- Last Ratings Update:02/29/2024
- Price as of 02/29/2024 :$13.69
- Net Assets:$402 Million
- NAV:$16.28
- Premium-15.91%
- Peer Rank:21 of 48
- Investment Rating:D+
- Performance:C-
- RiskC+
We rate Tekla Life Sciences Investors at D+. Negative factors that influence this rating include a well below average total return. The fund invests approximately 84% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
Total return ranks well below peers over the last three years. The Tekla Life Sciences Investors has returned an annual rate of 9.30% since inception. More recently, the fund has generated a total return of 5.83% in the last five years, -2.49% in the last three years, and 8.21% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 52% of them. It has also outpaced 23% of its competitors on a three year basis and 42% of them over the last year for the period ending 2/29/2024. On a year to date basis, HQL has returned 6.44%.
Downside risk has been above average. HQL has a draw down risk of -46.96%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 17.2%. This fund has had moderate volatility in its monthly performance over the last 36 months.
High expense ratio hinders performance. On total assets of $402.00 million, HQL maintains a high expense ratio compared to its Sector - Health/Biotechnology peers of 1.35% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As HQL is a closed end fund, it has no front end or back end load.